BEATBio is a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy for heart failure. BEATBio's technologies were developed by a founding scientific team from the University of Washington. BEATBio holds an exclusive, worldwide license from the University of Washington to a suite of technologies and associated intellectual property involving cardiovascular medicine, including gene and cell therapy, bioengineered materials and biological pace-makers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/17/13 | $2,500,000 | Seed |
CET Capital Partners | undisclosed |
